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Abstract
Background: The atherogenic lipoprotein phenotype is characterized by an increase in plasma triglycerides, a
decrease in high-density lipoprotein cholesterol (HDLc), and the prevalence of small, dense-low density lipoprotein
cholesterol (LDLc) particles. The aim of this study was to establish the importance of LDL particle size
measurement by gender in a group of patients with Metabolic Syndrome (MS) attending at a Cardiovascular Risk
Unit in Primary Care and their classification into phenotypes.
Subjects and methods: One hundred eighty-five patients (93 men and 92 women) from several areas in the
South of Spain, for a period of one year in a health centre were studied. Laboratory parameters included plasma
lipids, lipoproteins, low-density lipoprotein size and several atherogenic rates were determinated.
Results: We found differences by gender between anthropometric parameters, blood pressure and glucose
measures by MS status. Lipid profile was different in our two study groups, and gender differences in these
parameters within each group were also remarkable, in HDLc and Apo A-I values. According to LDL particle size,
we found males had smaller size than females, and patients with MS had also smaller than those without MS. We
observed inverse relationship between LDL particle size and triglycerides in patients with and without MS, and the
same relationship between all atherogenic rates in non-MS patients. When we considered our population in two
classes of phenotypes, lipid profile was worse in phenotype B.
Conclusion: In conclusion, we consider worthy the measurement of LDL particle size due to its relationship with
lipid profile and cardiovascular risk.
Keywords: Atherosclerosis, LDLC particle size, Metabolic Syndrome
1. Background
Atherosclerosis and its relevant vascular events includ-
ing cardiovascular disease (CVD), stroke and peripheral
arterial disease (PAD) have become a leading cause of
disability and mortality in modern society [1].
A lifestyle summarized as a lack of physical activity
and moderate-to-high intake calories seems to be one of
the most important causes of rapidly increasing preva-
lence of the metabolic syndrome (MS) [2].
The indicence of MS is rising and is recognized as a
major global health problem. Furthermore, recent guide-
lines for primary and secondary prevention of coronary
artery disease consider MS as a major risk factor for CVD
[3]. MS is defined as the clustering of abdominal obesity,
hypertension, insuline resistance, and dyslipidemia, char-
acterized by low high-density lipoprotein cholesterol
(HDLc) and high triglycerides (TG). Hypertriglyceridemia
and low HDLc are frequently associated with small dense-
low-density lipoprotein (LDLc); as a consequence, prepon-
derance of small dense-LDLc was described in MS [4].
LDL particles are a heterogeneous mixture of lipoproteins
differing in density, size, lipid composition, electrical charge,
and pathologic properties [5,6]. Determination of LDL
particle size is interesting, because the small-dense LDLc
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the arterial wall, a low affinity for the receptor, thereby
increasing its half-life plasma and low resistance to oxida-
tive stress. It has been described that oxidative modifica-
tions of lipoproteins leading to oxidized LDLc, results in
biological effects that may contribute to the process of
atherosclerosis [7].
Two distinct phenotypes were described: pattern B
with a predominance of small, dense LDL particles,
and pattern A with a higher proportion of large, more
buoyant LDL particles [8]. Although LDL particle size
is genetically determined [9], its phenotypic expression
may also be affected by environmental factors such as
drugs, diet, obesity or exercise. This trait has been
called “atherogenic dyslipidemia” and appears to
be highly heritable [8]. Factors that shift the LDL sub-
fractions profile towards larger particles may reduce
the risk of heart disease [10]. However, several studies
have shown that LDL particle size phenotype of risk
is not associated with risk fatal myocardial infarction
[11].
In order to make a proper evaluation a proper evalua-
tion of lipid-related risk, lipids ratios such as choles-
terol/HDLc ratio, TG/HDLc ratio, Apo-B/Apo-AI ratio
and AIP (atherogenic index of plasma [Log (TG/HDLC-
C)]) should be considered as proposed in several major
guidelines [12].
The aim of this study was to establish the importance
of LDL particle size measurement in a group of patients
with MS attending at a Cardiovascular Risk Unit in
Primary Care, by gender and their classification into
phenotypes.
2. Results
2.1. Subjects characteristics
Table 1 shows biochemical parameters and lipid profile
by separately by gender and SM status. The results are
expressed as mean ± standard deviation, and median
and interquartile range.
According to anthropometric parameters, values
(mean values) of weight and waist circumference were
significantly higher (p > 0.05) in males than in females
in those patients without associated MS, as well as levels
of blood glucose.
Regarding to classic lipid profile, there only were sig-
nificant differences by gender in levels of HDLc and
Apo A-I. Significantly higher values (p >0 . 0 5 )w e r e
observed in LDL particle size in women compared with
men in the group without MS. The results obtained are:
HDLc 59 [52-69] mg/dL (107 [82-131] in men and 66
[57-74] mg/dL in women); Apo A-I 160.8 ± 21.7 mg/dL
(155.4 ± 20.4 in men and 166.6 ± 21.8 mg/dL in
women); and LDL particle size 273.5 [271-274.7] Å
(271.9 [270.1-274] in men and 274.2 [273-275.4] Å in
women). There were no significant differences in the
other parameters.
In MS group, we observed values of HDLc: 52 [40-61]
mg/dL (45.5 [37-55.8] in men and 56 [49-72] mg/dL in
women) and Apo AI: 159.2 ± 30.6 mg/dL (147.9 ± 27.2
in men and 170.4 ± 29.9 mg/dL in women); they were
significantly higher (p > 0.05) in women and anthropo-
metric parameters of weight and waist circumference
have been found significantly different too. We also
found significant differences (p > 0.05) by sex in LDL
particle size, higher values in women (270.3 [266-273.6]
Å) than in men (267.9 [260.6-272] Å).
Distribution of LDL particle size in our population by
gender and MS status is shown in Figure 1.
2.2. Lipid profile and atherogenic rates
Results of Pearson’s correlation analysis between LDL
particle size (men and women together) and the other
variables (lipid profile and atherogenic rates) are shown
in Table 2.
LDL particle size was significantly (p > 0.05) negatively
correlated with total cholesterol (r = -0.38, p = 0.001),
triglycerides (r = -0.69, p > 0.001), LDLc (r = -0.31, p =
0.008), HDLc (r = 0.28, p = 0.019) and Apo-B (r =
-0.40, p = 0.001) in the group without SM. All athero-
genic rates (p > 0.001) were negatively correlated with
LDL particle size in this group. We have not found any
correlation between LDL particle size and Apo A-I, Apo
A-II or Lipoprotein (a).
In SM group, we only found significant differences
between particle size and triglycerides (r = -0.19, p =
0.041), Apo-B (r = -0.38, p > 0.001) and ApoB/ApoAI
ratio (r = -0.37, p > 0.001), negatively correlated. We
have not found any correlation in the rest of lipid profile
parameters.
2.3. Particle size phenotypes
Table 3 shows lipid profile (concentrations and ratios)
by particle size phenotype and SM status.
In the non-risk phenotype group (LDL particle size >
260Å), we found significant differences between the
groups with and without MS, in triglycerides levels (p >
0.001), HDLc (p = 0.001), and Apo-B (p = 0.031). In
addition, values of atherogenic rates: Apo B/Apo A-I
ratio (p = 0.024), plasma cholesterol/HDLc ratio (p =
0.001), plasma triglycerides/HDLc ratio (p > 0.001), log
(TG/HDLc) ratio (p > 0.001), were significantly higher
in patients with MS. LDL particle size was significantly
lower (p > 0.001) in MS patients, and all classic para-
meters of lipid profile of this group were higher in these
group.
When there was phenotype B (LDL particle size ≤
260Å), we only found significantly higher (p = 0.012)
values of Lipoprotein (a), when group without MS was
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Page 2 of 8Table 1 Characteristics of the study, by gender and MS status (N = 185)
Variable Without MS With MS p-value
3
Mean ± SD p-value
1 Mean ± SD p-value
2
N = 72 Men
(N = 37)
Women
(N = 35)
N = 113 Men
(N = 56)
Women
(N = 56)
Age (years) 52.36 ± 18.9 53.8 ± 15.4 50.9 ± 22.3 0.608 61 ± 13.8 59.1 ± 13.3 62.9 ± 14.2 0.068 0.002*
Weight (Kg) 75 ± 12.7 80.9 ± 11.2 68.9 ± 11.3 > 0.001* 86.1 ± 16.3 91.7 ± 12.04 80.5 ± 18.1 > 0.001* > 0.001*
Waist circumference (cm) 94.4 ± 11.1 98.4 ± 8.8 90.3 ± 11.9 0.001* 106.4 ± 11.4 109.1 ± 7.3 103.8 ± 13.9 0.016* > 0.001*
SBP (mm Hg) 128.6 ± 14.9 131.5 ± 13.1 125.4 ± 16.3 0.073 144.4 ± 15.9 143.6 ± 15.8 145.3 ± 16.1 0.369 > 0.001*
DBP (mm Hg) 78 ± 9.7 81.7 ± 9.4 74.1 ± 8.4 0.001* 84.1 ± 8.9 84.4 ± 8.9 83.9 ± 8.9 0.629 > 0.001*
Glucose (mg/dL) 99 [84.3-147] 106 [91-154.5] 87 [80-144] 0.024* 130.5 [105.3-172] 131 [104.5-163] 130 [106-185] 0.995 > 0.001*
Cholesterol (mg/dL) 189.6 ± 37.1 189.3 ± 41.6 189.9 ± 32.4 0.830 200.3 ± 40.7 194.7 ± 41.9 205.9 ± 39.1 0.083 0.118
TG (mg/dL) 103 [70.8-132] 113 [71.5-141] 84 [68-121] 0.061 149 [95.3-212] 156 [101.5-243] 128.5 [91-187] 0.080 > 0.001*
LDL-c (mg/dL) 107.2 ± 32.4 109.5 ± 35.2 104.7 ± 29.5 0.787 113.3 ± 33.6 112.1 ± 36.4 114.5 ± 30.9 0.459 0.274
HDL-c (mg/dL) 59 [52-69] 107 [82-131] 66 [57-74] > 0.001* 52 [40-61] 45.5 [37-55.8] 56 [49-72] > 0.001* > 0.001*
Apo A-I (mg/dL) 160.8 ± 21.7 155.4 ± 20.4 166.6 ± 21.8 0.039* 159.2 ± 30.6 147.9 ± 27.2 170.4 ± 29.9 > 0.001* 0.494
Apo A-II (mg/dL) 31 [28.5-34] 31 [28.3-34.8] 31 [28.5-32] 0.712 32 [27.8-39] 32 [27-39] 32.5 [28-39] 1.000 0.119
Apo B (mg/dL) 96.7 ± 24 100.9 ± 25.5 92.12 ± 21.7 0.147 108.6 ± 24.5 108.4 ± 22.6 108.9 ± 26.5 0.806 0.008*
Lipoprotein (a) (mg/dL) 12.7 [4.3-42.9] 15.9 [3.1-39.6] 12.7 [6.2-44.9] 0.516 16 [5.3-36.1] 13.1 [4.6-28.3] 19.2 [6.7-48.5] 0.258 0.845
LDL particle size (Å) 273.5 [271-274.7] 271.9 [270.1-274] 274.2 [273-275.4] 0.001* 269 [264.2-272.6] 267.9 [260.6-272] 270.3 [266-274] 0.039* > 0.001*
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: Triglycerides; LDL-c: dense-low density lipoprotein; HDL-c: high-density lipoprotein.
p-value
1: significance between male and female in non-MS patients.
p-value
2: significance between male and female in MS patients.
p-value
3: significance between non-MS and MS patients.
Notes: Data are mean ± SD, and median and interquartile range. * Statistically significant differences.
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8compared to patients with MS. However, values of lipid
profile parameters such as cholesterol, triglycerides,
LDLc, HDLc, Apo A-I and Apo-B were slightly higher
i nt h eg r o u pw i t h o u tM S .T h e r ew e r en os i g n i f i c a n t l y
differences (p = 0.114) in LDL particle size between
patients whitout and with MS when there was risk
phenotype.
Lipid profile by SM status and particle size phenotype
is shown in Table 4.
In non-MS group, significant differences were found
between particle size phenotypes and lipid parameters: TG
(p = 0.003), Apo-B (p = 0.025), Lipoprotein (a) (p = 0.005),
and all atherogenic rates (p >0 . 0 5 ) .
In MS group, we only founded significant differences:
TG (p >0 . 0 0 1 ) ,A p o - B( p = 0.014) and two atherogenic
rates (p > 0.001). We found significant differences
in LDL particle size in both study groups (p = 0.001 and
p > 0.001 respectively).
3. Subjects and methods
3.1. Study participants
One hundred eighty-five patients, 93 men (54 ± 14.3
years) and 92 women (58.3 ± 18.6 years), from several
areas in South of Spain for a period of one year in a
health centre participated in this study. Those patients
were attending at a Cardiovascular Risk Unit.
We used a control group of 35 patients (38.5 ± 14.1
years) without any cardiovascular risk factors such as
hypertension, diabetes mellitus type 2 or MS. Patients
with terminal, kidney, liver disease or thyroid dysfunc-
tion were excluded from the study.
Each participant underwent a physical examination,
personal interview, collection of biological specimens,
and other diagnostic tests. Permission was granted by
each community to conduct the study; written informed
consent was obtained from all participants.
3.2. Physical and metabolic measurements
Anthropometry parameters (weight, waist circumference)
were performed with participants fasting, according to
standard procedures. Abdominal obesity was defined
using Adult Treatment Panel III (ATP III) criteria [13].
Samples of whole blood, plasma and serum were collected
from each participant and stored at -80°C.
3.3. Definitions of metabolic syndrome
MS was defined according to ATP III criteria [13] as
meeting three or more of the following criteria: waist
circumference 102 cm for men, 88 cm for women;
triglycerides ≥ 150 mg/dL (0.59 mmol/L); HDLc > 40
mg/dL (1.30 mmol/L) for men, > 50 mg/dL (1.04 mmol/
L) for women; arterial hypertension (systolic blood pres-
sure ≥ 130 mmHg, diastolic blood pressure ≥ mmHg);
fasting glucose ≥ 100 mg/dL (5.56 mmol/L).
3.4. Laboratory measurements
Total cholesterol, HDLc and triglycerides were
measured by an analyzer Hitachi Modular P (Roche Diag-
nostics
®) using a homogeneous enzymatic colorimetric
test.
LDLc was estimated using the originally formula
described by Friedewald, Levy and Fredrickson [14]. A
limitation of this estimate is not to be used when trigly-
cerides are greater than 200 mg/dL.
Determination of apo A-I, apo A-II, apo-B and lipo-
protein (a) were performed on an immunonephelometer
analyzer (BN Prospec, Siemens Diagnostics
®) using mono-
and polyclonal antibodies. We have considered several
atherogenic rates: cholesterol/HDLc ratio, TG/HDLc ratio,
Figure 1 Distribution of LDL particle size in our population by
gender and MS status.
Table 2 Pearson’s coefficient of LDL particle size with
lipid profile and atherogenic rates in our population
LDL particle size Without MS
(N = 72)
With MS
(N = 113)
r p-value r p-value
Plasma cholesterol (mg/dL) -0.38 0.001* -0.02 0.859
Plasma triglycerides (mg/dL) -0.69 > 0.001* -0.19 0.041*
LDL cholesterol (mg/dL) -0.31 0.008* 0.07 0.472
HDL cholesterol (mg/dL) 0.28 0.019* 0.05 0.631
Apo A-I (mg/dL) 0.03 0.833 0.14 0.173
Apo A-II (mg/dL) -0.22 0.071 0.01 0.893
Apo B (mg/dL) -0.40 0.001* -0.38 > 0.001*
Lipoprotein (a) (mg/dL) 0.07 0.561 0.02 0.851
Apo B/Apo A-I ratio -0.37 0.002* -0.37 > 0.001*
Plasma cholesterol/HDL-c ratio -0.50 > 0.001* -0.09 0.343
Plasma triglycerides/HDL-c ratio -0.67 > 0.001* -0.18 0.068
Log (TG/HDL-c) ratio -0.59 > 0.001* -0.18 0.056
* Statistically significant differences.
Sancho-Rodríguez et al. Lipids in Health and Disease 2011, 10:162
http://www.lipidworld.com/content/10/1/162
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[Log (TG/HDLC-C)]). These rates have been calculated
from each parameter of classic lipid profile.
3.5. Lipoprotein subfraction profile
LDLc subfractions were analyzed by Lipoprint Quanti-
metrix System
® (Quantimetrix Corporation), which uses
gel electrophoresis tube with 3% polyacrylamide, follow-
ing the manufacturer’s instructions and procedures
described [15]. This system separates the various lipo-
protein subfractions according to their different size and
electrical charge. It allows isolate up to 12 lipoprotein
fractions, and system provides information about the
average diameter of LDLc particles, estimated by the
algorithm developed by Kazumi et al. [15]. This method
has been recently evaluated by our working group [16].
According to the LDLc electrophoretic profile, two
phenotypes can be defined: phenotype A with normal
Table 3 Lipid profile: concentrations and ratios, by particle size phenotype and MS status (N = 185)
Phenotype A (> 260 Å)
(N = 127)
Phenotype B (≤ 260 Å)
(N = 58)
p-value
3
No MS MS p-value
1 No MS MS p-value
2
Plasma cholesterol (mg/dL) 188 ± 35.9 196.1 ± 83.6 0.279 245 ± 56 227 ± 48 0.721 0.001*
Plasma triglycerides (mg/dL) 101 [70-129.3] 129 [91-195] > 0.001* 282 [265-298] 245 [178-296] 0.529 > 0.001*
LDL cholesterol (mg/dL) 106.4 ± 31.8 112 ± 34 0.413 137 ± 54 124 ± 32 1.000 0.064
HDL cholesterol (mg/dL) 60 [52-69] 53 [41-63] 0.001* 52 [47-56] 42 [38-52] 0.441 0.004*
Apo A-I (mg/dL) 160.6 ± 22.1 159.37 ± 31.7 0.632 168 ± 4.24 158.7 ± 26.5 0.400 0.328
Apo A-II (mg/dL) 31 [28-33] 32 [27-38] 0.212 36.5 [35-38] 34 [30-41] 0.857 0.337
Apo B (mg/dL) 95.4 ± 23.1 105.1 ± 21.4 0.031* 139 ± 24.1 122.5 ± 31.2 0.400 0.001*
Lipoprotein (a) (mg/dL) 18.6 [4.9-43] 14.3 [4.2-33.7] 0.405 1.25 [1.2-1.3] 19.5 [12.9-47.3] 0.012* 0.353
Apo B/Apo A-I ratio 0.60 ± 0.16 0.69 ± 0.19 0.024* 0.83 ± 0.12 0.78 ± 0.18 0.610 0.001*
Plasma cholesterol/HDL-c ratio 3.22 ± 0.84 3.84 ± 1.18 0.001* 4.72 ± 0.50 4.82 ± 1.17 0.889 > 0.001*
Plasma triglycerides/HDL-c ratio 1.65 [1.13-2.45] 2.49 [1.53-3.67] > 0.001* 5.55 [4.73-6.34] 5.49 [3.99-6.85] 0.963 > 0.001*
Log (TG/HDL-c) ratio 0.20 ± 0.24 0.38 ± 0.29 > 0.001* 0.74 ± 0.08 0.72 ± 0.19 0.963 > 0.001*
LDL particle size (Å) 273.6 [271.1-274.7] 271.2 [267.7-273.7] > 0.001* 255.25 [255-255.5] 259 [257.6-260] 0.114 > 0.001*
Notes: Data are mean ± SD, and median and interquartile range. * Statistically significant differences.
p-value
1: significance between MS and non-MS in phenotype A patients.
p-value
2: significance between MS and non-MS in phenotype B patients.
p-value
3: significance between phenotypes.
Table 4 Lipid profile: concentrations and ratios, by MS status and particle size phenotype (N = 185)
No SM
(N = 72)
SM
(N = 113)
Phenotype A
(> 260 Å)
Phenotype B
(≤ 260 Å)
p-value Phenotype A
(> 260 Å)
Phenotype B
(≤ 260 Å)
p-value
Plasma cholesterol (mg/dL) 188 ± 35.9 245 ± 56 0.103 196.1 ± 83.6 227 ± 48 0.009*
Plasma triglycerides (mg/dL) 101 [70-129.3] 282 [265-298] 0.003* 129 [91-195] 245 [178-296] > 0.001*
LDL cholesterol (mg/dL) 106.4 ± 31.8 137 ± 54 0.379 112 ± 34 124 ± 32 0.151
HDL cholesterol (mg/dL) 60 [52-69] 52 [47-56] 0.329 53 [41-63] 42 [38-52] 0.072
Apo A-I (mg/dL) 160.6 ± 22.1 168 ± 4.24 0.538 159.37 ± 31.7 158.7 ± 26.5 0.270
Apo A-II (mg/dL) 31 [28-33] 36.5 [35-38] 0.069 32 [27-38] 34 [30-41] 0.934
Apo B (mg/dL) 95.4 ± 23.1 139 ± 24.1 0.025* 105.1 ± 21.4 122.5 ± 31.2 0.014*
Lipoprotein (a) (mg/dL) 18.6 [4.9-43] 1.25 [1.2-1.3] 0.005* 14.3 [4.2-33.7] 19.5 [12.9-47.3] 0.844
Apo B/Apo A-I ratio 0.60 ± 0.16 0.83 ± 0.12 0.050* 0.69 ± 0.19 0.78 ± 0.18 0.023
Plasma cholesterol/HDL-c ratio 3.22 ± 0.84 4.72 ± 0.50 0.016* 3.84 ± 1.18 4.82 ± 1.17 0.001
Plasma triglycerides/HDL-c ratio 1.65 [1.13-2.45] 5.55 [4.73-6.34] 0.003* 2.49 [1.53-3.67] 5.49 [3.99-6.85] > 0.001*
Log (TG/HDL-c) ratio 0.20 ± 0.24 0.74 ± 0.08 0.003* 0.38 ± 0.29 0.72 ± 0.19 > 0.001*
LDL particle size (Å) 273.6 [271.1-274.7] 255.25 [255-255.5] 0.001* 271.2 [267.7-273.7] 259 [257.6-260] > 0.001*
Notes: Data are mean ± SD, and median and interquartile range. * Statistically significant differences.
p-value
1: significance between phenotype MS in non-MS patients.
p-value
2: significance between phenotype MS in MS patients.
p-value
3: significance between MS status.
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phenotype non-A (phenotype B) where total cholesterol
mass of the LDLc subfractions is intermediate-low.
The average particle size reported by Lipoprint profile
is the weighted average (calculated from the area under
the curve for each subfraction) of the particle sizes of all
the LDLc peaks present in the sample. Based on this
size cut-off works out to be above or equal to 260 nm
for phenotype A (normal size) and less than for non-A
(we call this B).
3.6. Statistical analyses
The normal distribution of variables was tested using
the Kolmogorov-Smirnov test. Quantitative variables are
summarized as mean (m) and standard deviation (SD)
and confidence interval 95% (CI), for those who fol-
lowed a normal distribution and as median and inter-
quartile range otherwise.
To compare means was applied Student t test for nor-
mally distributed variables, Mann-Whitney U-test for
skewed variables.
In addition, the correlation between quantitative vari-
ables was assessed by linear regression according to
Pearson or Spearman skewed or normally distributed
variables. Results were considered significant with p-
values > 0.05. All statistics were analyzed by using SPSS
for Windows v15.0 (Chicago, Illinois, USA).
4. Discussion
Predominance of small, dense low-density lipoprotein
cholesterol (LDLc) has been designated as an emerging
cardiovascular risk factor by the National Cholesterol
Education Program Adult Treatment Panel III [3]. MS is
a disease with an impact on our society, resulting in
large cardiovascular problems. We have considered the
importance of evaluating LDL particle size in a popula-
tion with MS.
In our observational study, we found differences by
gender in anthropometric measures (weight and waist
circumference), blood pressure and glucose between
patients with and without MS. This is in agreement
with Sohn et al. [17], who found significant differences
by gender when compared the association between MS
and health-related quality of life of Korean population.
In addition, lipid profile was different in all parameters
in our two study groups, and gender differences in these
parameters within each group were also remarkable in
HDLc and Apo A-I values.
When we studied lipid profile (cholesterol, TG, LDLc,
HDLc, Apo A-I, Apo A-II, Apo-B, and Lipoprotein (a))
by gender in those patients without and with MS, only
significant differences in HDLc and Apo A-I were
found. Differences we have found by gender and MS
status in LDL particle size are consistent with other
authors [18], who showed that males had smaller LDL
particle size than females; they studied the presence of
small dense LDLc depending on gender and metabolic
syndrome, and they also found that patients with MS
had LDL particle sizes smaller than those without this
syndrome.
Using Pearson’s coefficient of LDL particle size with
lipid profile and atherogenic rates, we observed inverse
relationship between LDL particle size with levels of tri-
glycerides in patients with and without MS, in agree-
ment with the results of Austin [19] and Griffin et al.
[20]; they showed that predominance of small, dense
LDLc was associated with an increased risk of coronary
artery disease (CAD). Although another study showed
that LDL particle size is rarely a significant and indepen-
dent predictor of CAD risk [21] in patients without MS.
We have also observed an inverse relationship between
LDL particle size and all atherogenic rates in non-MS
patients, likes Y o s h i d ae ta l .[ 2 2 ] ,w h os h o w e dt h a t
LDLc/Apo B, total cholesterol/TG and LDLc/TG ratios
c o u l db eu s e dt op r e d i c tt h ep r e s e n c eo fs m a l ld e n s e ,
but the superiority of these ratios over plasma TG levels
alone was not established. In a recent study [23], results
indicated a consistent degree of discordance between
LDL particle size and lipid indices, as shown our data in
SM patients, in which we only found signicantly differ-
ences between LDL particle size and Apo B/Apo A-I
ratio.
In the study of phenotypes of LDL particle size by SM
status, we established two classes of phenotypes based
on LDL particle size according to studies of Griffin [20]
and Austin and Krauss [8]; they set the cut-off at 255 Å,
while Rizzo and Berneis [24] used 258 Å. Other authors
[25], classified LDL particle size according to a value of
260 Å; establishing a non-risk phenotype A (> 260 Å),
another risk B (≤ 255 Å), and a third intermediate phe-
notype I (255-260 Å). We have classified study popula-
tion with a cut-off of 260 Å, grouping phenotype B and
intermediate, separating group A (no risk). In our study,
only 15% of total population (with and without MS) had
phenotype B; however, Austin et al. [26] suggested that
about 30% of the population could be defined as having
the phenotype B, whereas 70% of the population could
be classified into phenotype A or into intermediate
phenotype.
Into these phenotypes, in non-risk group we found
differences in plasma triglycerides, HDLc, Apo-B levels
and all atherogenic rates. According to Apo B/Apo A-I
ratio, we found significantly differences in non-risk phe-
notype. Talmud et al. [ 2 7 ]s h o w e dt h a tA p oB / A p oA - I
ratio was associated with the strongest effects on relative
risk of coronary heart disease, although some authors
showed great discordance compared with either Apo-B
or Apo-B/Apo-AI ratio [28].
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Page 6 of 8When we compared patients with and without MS,
significant differences were only found in risk phenotype
B in lipoprotein (a) levels; we believe that it could be
explained by the small sample size (n = 18). Interrela-
tions of two lipoprotein (a) constituents still remain to
be elucidated. It is assumed that, once synthesized, apo
(a) would associate with LDLc particles currently avail-
able in plasma, regardless of their size and density.
According to Nakajima et al. [29], composition of lipo-
protein (a) in an individual would depend on the combi-
nation of a genetically controlled apo(a) isoform and a
predominant circulating LDLc subclass.
Surprisingly, LDL particle size was smaller in pheno-
type B patients without MS; this may be due to intrinsic
patient factors such as age, gender, dyslipemia or even
to other cardiovascular risk factors. We could think that
phenotype B ‘per se’ could be considered as a cardiovas-
cular risk factor.
By MS status, TG, Lp(a) levels and all atherogenic
rates were significantly different in non-MS patients and
worse in risk phenotype. In MS patients, cholesterol,
TG, Apo-B levels and two atherogenic rates were also
significantly different.
In conclusion, our data point to LDL particle size is
higher in women than in men and in patients without
MS. Respect to lipid profile, we also found differences
by gender and between groups of patients with and
without MS, but these differences were most evident by
MS status than by gender.
LDL particle size was inversely correlated mainly with
TG and Apo-B levels in presence and absence of MS,
although particle size was also negatively significantly
correlated with all atherogenic rates in patients without
MS.
Phenotype B lipid profile and LDL particle size was
worse in non-MS patients. Patients with MS and pheno-
type B had worse lipid profile and lower LDL particle
size, but only significant differences were found TG,
Apo B and those atherogenic rates TG related.
We think that LDL particle size could be a worthy
marker of risk by itself. Further studies in patient groups
with several risk factors will make it possible to establish
the importance of particle size of LDL, compared to
classic lipid profile in suffered cardiovascular events.
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